Case presentation {#Sec1}
=================

A 33-year-old female patient with relapsing-onset multiple sclerosis (MS) was electively admitted to the Belgian Nationaal Multiple Sclerose Centrum for neurological assessment and multidisciplinary rehabilitation on March 9, 2020. Such programs are covered by the local reimbursement system and considered to be part of the standard medical care. She was diagnosed with MS in 2004 following an episode of optic neuritis of her right eye. Subsequent relapses resulted in spastic paraparesis and cerebellar dysfunction presenting with truncal and appendicular ataxia. Off-label disease-modifying MS therapy with rituximab, an anti-CD20-mediated B cell depleting agent \[[@CR1]\], was given as a single intravenous course of 1000 mg on October 11, 2019, after a period of disease progression with clinical and radiological inflammatory activity, despite treatment with subcutaneous interferon-beta-1a. Expanded Disability Status Scale score was 8.0 at that time \[[@CR2]\], and remained stable ever since. Seven days after admission, our patient developed fever, muscle soreness, headache, productive cough, and mild dyspnea. Blood analysis revealed an elevated C-reactive protein level (35.6 mg/L, normal value \< 5.0 mg/L), lymphopenia (0.3 × 10^9^/L, normal range 1.2--3.6 × 10^9^/L), and neutropenia (1.6 × 10^9^/L, normal range 2.5--7.8 × 10^9^/L), whereas corresponding baseline values (routinely measured on the day of admission) all had been normal. Considering the recent "coronavirus disease of 2019" (COVID-19) outbreak \[[@CR3]\], and after identifying a potentially contaminating visit, a nasopharyngeal swab for real-time reverse transcriptase polymerase chain reaction detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)---i.e., the culprit agent in COVID-19---was ordered and came back positive. Strict hygienic and in-hospital isolation measures were applied to reduce the risk of disease spread. The patient fully recovered under symptomatic management over approximately 1 week; blood oxygen saturation levels remained \> 96% during the entire disease period. Blood sampling around that time demonstrated a (nearly) complete restoration of the abovementioned abnormalities. Additional cellular immunology, performed 1 week after the positive COVID-19 test, showed unaffected numbers of CD4+ and CD8+ T lymphocytes, as well as natural killer cells. CD19+ B cell levels were, as expected with rituximab, reduced to 0.3% of the total lymphocyte population (normal range 5.0--20.0%). Hypogammaglobulinemia in the IgG subfraction was observed (7.11 g/L, normal range 7.51--15.60 g/L) and D-dimers were elevated (738 μg/L, normal value \< 500 μg/L), in accordance with previous data in COVID-19 patients \[[@CR4]\].

Discussion {#Sec2}
==========

We present the first report of a patient with MS who was formally diagnosed with COVID-19 and experienced a favorable clinical outcome despite immunosuppressive therapy with rituximab. SARS-CoV-2 is a highly virulent pathogen with a considerable case fatality rate notwithstanding extensive global effort. Presumed risk factors for severe disease with development of acute respiratory distress syndrome include diabetes mellitus, arterial hypertension, heart failure, and chronic pulmonary disease \[[@CR3]\]. Upon entering the body, the coronavirus rapidly infects alveolar epithelial cells through the angiotensin-converting enzyme 2 receptor. Toll-like, retinoic acid-inducible gene-I-like and pathogen-recognition receptors play a key role in initiating viral clearing by activation of downstream elements such as nuclear factor--kappa B, interferons, and interleukins \[[@CR5]\]. These innate immune mechanisms are not expected to be deeply affected by rituximab, given its specific mode of action, but may become easily overturned by SARS-CoV-2, as, for instance, the N-protein located at the genomic level is a powerful antagonist of the host interferon system \[[@CR5]\]. CD8+ T cell counts can rise up to 80% of total inflammatory cell population in the pulmonary interstitium during COVID-19, emphasizing the importance of this cell type in host defense \[[@CR6]\]. Corresponding values were normal in our patient, likely contributing to an effective adaptive immune response. Humoral factors, mediated by the activation and maturation of naïve B-lymphocytes, are critically important to establish long-lasting immune recognition, but could be less significant in the initial antiviral response, translating to a good clinical recovery despite medication-induced B cell lymphopenia. In another study, mice were infected with the related Middle East respiratory syndrome coronavirus, and a model was created with animals deficient in T cells, B cells or both. T lymphocyte deficiency was associated with absence of viral clearance, whereas mice lacking B cells were able to overcome the infection \[[@CR7]\]. Theoretically, it might be hypothesized that some forms of immunosuppression offer a protective effect versus the cytokine release storm observed in COVID-19. Hence, certain cytokines (e.g., interleukin 2 and 7, granulocyte-colony stimulating factor, and tumor necrosis factor alpha) are upregulated during infection and are associated with adverse outcomes (i.e., need for intensive care unit admission) in affected subjects \[[@CR8]\]. Modulating these pathways might prove beneficial in the approach of this disorder, yet, the precise role of rituximab in that regard remains to be elucidated.

Invasive viral disease has not emerged as a major concern from clinical trial development and postmarketing surveillance of anti-CD20 therapies in individuals with MS. Nonetheless, many national guidelines are currently recommending suspended dosing, where possible, because of the COVID-19 pandemic. Maximizing risk avoidance during a global infectious threat seems reasonable but we must remain equally vigilant for the return of disease activity in highly active MS. Our findings illustrate that SARS-CoV-2 infection does not necessarily translate into a poor prognosis in MS patients who are receiving B cell depleting agents, and are in line with recent reports of mild COVID-19 in subjects treated with ocrelizumab \[[@CR9]\]. Additional data and more extensive evaluations, however, are required to make a more firm safety claim and, for a number of reasons, caution is warranted before generalizing our observations. First, rituximab and ocrelizumab are occasionally associated with severe neutropenia and/or more profound hypogammaglobulinemia \[[@CR1]\], which may impose an additional stress on the immune system. Second, our patient had none of the other medical risk factors for worse COVID-19 prognosis (see above) and was a non-smoker. Third, B cell levels in her blood were no longer fully depleted (0.3%) at the time of infection, as the previous rituximab administration dated from more than 4 months before. Fourth and finally, a uniform dosing scheme exists for ocrelizumab but this is less the case for rituximab, where, for example, 6-monthly intravenous courses of 2000 mg (usually divided over two administrations of 1000 mg each, with a 2-week interval) are not uncommon. At this moment, within the context of the ongoing COVID-19 crisis, we advocate for carefully balanced case-by-case treatment decisions, including monitoring of disease activity and CD19+ B cell repopulation, regarding anti-CD20 agents in subjects with MS.
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